Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BSLK vs NIVF: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NIVF Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 5–3 Matrix Metrics)

NIVF Overall Winner 6-Pillar Tally: BSLK 1 – 2 NIVF (3 Tie) Matrix Metrics: BSLK 3 – 5 NIVF

As of Nov 16, 2026, NewGenIvf Group Limited Class A (NIVF) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas NIVF carries 42.4/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin).

  • Growth vs. Quality Trade-Off: NIVF earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. BSLK 41.2/100 SELL) and 0.07β · 3093% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BSLK vs NIVF
BSLK NASDAQ
Bolt Projects Holdings, Inc. Common Stock
Industrial Organic Chemicals
$0.58
-27.01% 1D
Market Cap $7.1M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 4.04β · 148% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.4%), weak momentum, RSI 20
RSI-14: 19.8 · SMA20: $1.63 · SMA50: $1.95
NIVF NASDAQ Head-to-Head Winner
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.20
-11.33% 1D
Market Cap $369,508
TTM Revenue $4.6M
Forward P/E N/M
Beta / 30D Vol 0.07β · 3093% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 40.0 Fund 40.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.1%), weak momentum, RSI 38
RSI-14: 38.2 · SMA20: $0.64 · SMA50: $0.54

6-Pillar Scorecard Institutional Category Breakdown (BSLK 1 – 2 NIVF)

Columns: Metric · BSLK · NIVF
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 0.1x N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x 0.1x
2. Growth & Scale BSLK
Revenue Growth (YoY) +7300.0% -4.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.1M $4.6M
Market Cap $7.1M $369,508
3. Profitability & Quality NIVF
Gross Margin 3.2% 23.9%
Operating Margin -1179.5% -238.2%
Net Profit Margin 0.0% 24.2%
Return on Equity (ROE) -4288.3% 5.5%
4. Balance Sheet & Cash Flow NIVF
Cash Generation (TTM) -$5.4M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.2M Net Debt $733.75 Book/Sh · 5.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BSLK (3) vs NIVF (5)
Institutional Metric BSLK NIVF Criterion Row Edge
Market Capitalization
Scale
$7.1M $369,508 Larger Scale Tie
Trailing P/E Ratio
Valuation
0.1x N/M Lower Multiple BSLK
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+7300.0% -4.7% Higher Growth BSLK
Operating Margin (TTM)
Profitability
-1179.5% -238.2% Higher Margin NIVF
Net Profit Margin
Profitability
0.0% 24.2% Higher Margin NIVF
Return on Equity (ROE)
Capital Efficiency
-4288.3% 5.5% Higher ROE NIVF
52-Week Range Position
Momentum
0% ($1–$25) 5% ($0–$3) Stronger Trend NIVF
Beta / 30D Volatility
Risk Regime
4.04β · 148% Vol 0.07β · 3093% Vol Lower Realized Risk BSLK
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 42.4 / 100 (HOLD) Higher Composite NIVF
Trailing 12M Revenue (USD)
Operating Scale
$3.1M $4.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.2% 23.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.4M ($8.2M Net Debt) -$11M EBITDA ($733.75 Book/Sh · 5.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NIVF +18.53 pp
BSLK: -73.85% · NIVF: -55.32%
3M Horizon NIVF +149.83 pp
BSLK: -69.47% · NIVF: +80.36%
6M Horizon NIVF +149.83 pp
BSLK: -69.47% · NIVF: +80.36%
1Y Horizon NIVF +149.83 pp
BSLK: -69.47% · NIVF: +80.36%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period BSLK Revenue NIVF Revenue BSLK Op. Margin NIVF Op. Margin Margin Leader
Q4 '24 $10M N/A -504.4% N/A BSLK
Q1 '25 $0M N/A -3157.9% N/A BSLK
Q2 '25 $10M N/A -370.0% N/A BSLK
Q3 '25 $0M $10M -1179.5% -195.9% NIVF
Q4 '25 N/A $10M N/A -349.1% NIVF

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BSLK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BSLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NIVF UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NIVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BSLK Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $7.1M market capitalization and -1179.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NIVF Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $369,508 market capitalization and -238.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BSLK vs NIVF Key Questions & Quantitative Answers

As of Nov 16, 2026, NewGenIvf Group Limited Class A (NIVF) is the stronger overall head-to-head candidate over Bolt Projects Holdings, Inc. (BSLK) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BSLK carries a Unified Composite Score of 41.2/100 (SELL) at $0.58 (N/M Forward P/E, -1179.5% operating margin), whereas NIVF carries 42.4/100 (HOLD) at $0.20 (N/M Forward P/E, -238.2% operating margin). Growth vs. Quality Trade-Off: NIVF earns the overall head-to-head edge with a stronger Unified Composite Score (42.4/100 HOLD vs. BSLK 41.2/100 SELL) and 0.07β · 3093% Vol risk profile, whereas BSLK leads top-line expansion (+7300.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BSLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.8); meanwhile NIVF is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BSLK leads the Growth & Scale pillar: BSLK posts +7300.0% YoY revenue growth and +0.0% YoY earnings growth on $3.1M TTM revenue (3.2% gross margin, -1179.5% operating margin), compared with NIVF at -4.7% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (23.9% gross margin, -238.2% operating margin). Across the 5-period historical trajectory (Q4 '24 to Q4 '25), BSLK cumulative revenue shifted +0.0% while NIVF shifted +0.0%. In operating R&D and SG&A reinvestment, BSLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NIVF.

BSLK and NIVF trade at balanced relative valuation multiples. BSLK trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas NIVF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BSLK (-4288.3% ROE) versus NIVF (5.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BSLK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.04β · 148% Vol realized risk). By comparison, NIVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 3093% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.